Author:
Yoon Ji Hyun,Kim Jae Hui,Kim Chul Gu,Kim Jong Woo
Abstract
Abstract
Background
Information regarding incidence of treatment plan changes may be useful when discussing postoperative treatment plans for patients. Moreover, it may help establish a standardized postoperative treatment plan. This study aimed to evaluate the incidence of early complications requiring treatment plan changes in patients following vitreoretinal surgery and investigate its risk factors.
Methods
This single-center retrospective study included 465 patients who had undergone vitreoretinal surgery. The reasons, incidence, and timing of treatment plan changes within 14 days of surgery were identified. Potential factors associated with the changes, such as patient demographics, surgeon’s experience, diagnoses, and type of surgery were also analyzed.
Results
The treatment plan was changed in 76 patients (16.3%) at a mean of 4.0 ± 3.2 days after vitreoretinal surgery. The reasons for the plan changes were increased intraocular pressure (IIOP) in 66(86.8%), intraocular inflammation in 2(2.6%), corneal edema in 3(3.9%), leakage from the sclerotomy wound in 3(3.9%) patients, and combined IIOP and intraocular inflammation in 2(2.6%). The date of discharge was postponed because of treatment plan changes in 17 patients (22.4%). The incidence of plan changes was higher in patients who underwent gas or oil tamponade (P < 0.001) and those who underwent surgery performed by less experienced surgeons (P = 0.034).
Conclusions
Treatment plan was changed in 16.3% of patients after vitreoretinal surgery. The risk of treatment plan changes was associated with the surgeon’s experience in vitreoretinal surgery and the type of surgery. These results should be considered when establishing standardized care plans for patients who require vitreoretinal surgery.
Publisher
Springer Science and Business Media LLC
Subject
Ophthalmology,General Medicine
Reference28 articles.
1. Popovic MM, Muni RH, Nichani P, Kertes PJ. Pars plana vitrectomy, scleral buckle, and pneumatic retinopexy for the management of rhegmatogenous retinal detachment: a meta-analysis. Surv Ophthalmol 2021.
2. Glassman AR, Beaulieu WT, Maguire MG, et al. Visual acuity, vitreous hemorrhage, and other ocular outcomes after vitrectomy vs aflibercept for vitreous hemorrhage due to Diabetic Retinopathy: a secondary analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021;139:725–33.
3. Elhusseiny AM, Schwartz SG, Flynn HW Jr, Smiddy WE. Long-term outcomes after Macular Hole surgery. Ophthalmol Retina. 2020;4:369–76.
4. Far PM, Yeung SC, Ma PE et al. The effect of internal limiting membrane peel for idiopathic epiretinal membrane surgery: a systematic review of randomized controlled trials. Am J Ophthalmol 2021.
5. Arikan Yorgun M, Toklu Y, Mutlu M, Ozen U. Clinical outcomes of 25-gauge vitrectomy surgery for vitreoretinal diseases: comparison of vitrectomy alone and phaco-vitrectomy. Int J Ophthalmol. 2016;9:1163–9.